Vpriv Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to clinical acceptance of enzyme replacement therapies, improved diagnosis of gaucher disease, availability of recombinant biologics, expansion of specialty infusion centers, increased physician familiarity with lysosomal disorders.

The growth in the forecast period can be attributed to expansion of rare disease treatment access, rising investments in next-generation enzyme therapies, growing demand for personalized dosing strategies, advancements in recombinant protein manufacturing, increasing focus on lifelong disease management. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, rising focus on long-term rare disease management, growing use of recombinant enzyme technologies, expansion of personalized treatment regimens, enhanced emphasis on disease progression control.

The rising healthcare spending is expected to drive the growth of the VPRIV market. Healthcare expenditure is fueled by factors such as aging populations, advancements in medical technology, and the increasing prevalence of chronic and rare diseases. Higher healthcare spending supports VPRIV by enabling wider access to advanced enzyme replacement therapies, improving affordability and availability for patients with Gaucher disease type 1, and backing investments in diagnostic tools and healthcare infrastructure for rare diseases. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, a notable increase compared with the 0.9% growth in 2022. Therefore, rising healthcare spending is driving the growth of the VPRIV market.

The rise in personalized medicine is also expected to propel the VPRIV market forward. Personalized medicine tailors treatments to an individual’s genetic profile, lifestyle, and specific health conditions. This approach is advancing due to improvements in genomics, greater precision in therapies, and the ability to target diseases based on unique genetic characteristics. VPRIV supports personalized medicine by offering targeted enzyme replacement therapy for Gaucher disease, customized to patient needs. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a substantial increase from six approvals in 2022. Therefore, the rise in personalized medicine is driving the growth of the VPRIV market.

The increasing acceptance of biologics is another factor expected to propel the VPRIV market. Biologics are medical products derived from living organisms, including proteins, vaccines, and gene therapies, used to treat complex and rare conditions. Their growing acceptance is driven by their effectiveness in providing targeted and personalized treatment options. VPRIV exemplifies biologics by offering an enzyme replacement therapy specifically for Gaucher disease type 1, highlighting the potential of biologic therapies to address complex genetic disorders. For instance, in August 2025, according to the National Institutes of Health (NIH), a US-based government medical research agency, the FDA approved 50 novel drugs in 2024, including 16 biologics, with six biologic approvals occurring in the first half of the year alone, emphasizing the growing role of biologics in the therapeutic landscape. Therefore, increased acceptance of biologics is driving the growth of the VPRIV market.

Major companies operating in the vpriv market are Takeda Pharmaceutical Company Limited.

North America was the largest region in the vpriv market in 2025. The regions covered in the vpriv market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vpriv market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the vpriv market by increasing costs of imported bioreactors, recombinant protein processing equipment, sterile formulation systems, and cold-chain logistics required for enzyme replacement therapy production. North America and Europe are most affected due to reliance on cross-border biologics manufacturing and distribution networks. These tariffs are contributing to higher treatment costs and operational pressures on specialty pharmacies. However, they are also encouraging regional biologics manufacturing, domestic enzyme production capabilities, and long-term investments in rare disease therapy infrastructure.

The vpriv market research report is one of a series of new reports that provides vpriv market statistics, including vpriv industry global market size, regional shares, competitors with a vpriv market share, detailed vpriv market segments, market trends and opportunities, and any further data you may need to thrive in the vpriv industry. This vpriv market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vpriv (velaglucerase alfa) is a recombinant enzyme replacement therapy used for the long-term treatment of Gaucher disease type 1, a rare genetic disorder caused by a deficiency of the enzyme glucocerebrosidase. It works by replacing the missing or deficient enzyme, reducing the accumulation of fatty substances and alleviating symptoms associated with the disease.

The primary indications for Vpriv include type 1 Gaucher disease and type 3 Gaucher disease. Type 1 Gaucher disease is caused by a deficiency of glucocerebrosidase, an enzyme needed to break down the fatty substance glucocerebroside. Vpriv is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, and is used by adult, pediatric, and geriatric patients.

The vpriv market consists of sales of infusion equipment, supportive care medications, diagnostic tools, and patient monitoring tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.